Table 1.
Clinical characteristics of patients and control individuals
|
|
Cohort 1 (n = 44)
|
Cohort 2 (n = 45)
|
| Age (yr), average | 46.0 ± 10.24 | 47.2 ± 11.02 |
| Gender | ||
| Male | 36 | 41 |
| Female | 8 | 4 |
| Category | ||
| HBV infected group | 10 | 8 |
| Liver cirrhosis group | 10 | 10 |
| HCC tumor group | 24 | 27 |
| BCLC stage1 | ||
| Stage A | 8 | 9 |
| Stage B | 8 | 8 |
| Stage C | 8 | 10 |
| Drinking history | ||
| No daily drinking2 | 29 | 21 |
| Daily drinking3 | 15 | 24 |
| Intake of alcohol (g/d), average | 97 ± 143 | 121 ± 121 |
| AFP (ng/mL) of HCC, average | 350.75 ± 361.98 | 221.86 ± 274.84 |
| CA19-9 (KU/L) of HCC, average | 44.63 ± 59.17 | 28.96 ± 59.2 |
| CEA (ng/mL) of HCC, average | 2.98 ± 1.98 | 3.94 ± 7.32 |
1
Barcelona Clinic Liver Cancer stage.
2
Daily consumption of alcohol under 12 g was defined as “No daily drinking”.
3
Daily drinking greater than or equal to 12 g of alcohol was defined as “Daily drinking”. HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; AFP: αfetoprotein.